Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis

Company Overview

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $18.60 to $19.98
• 50-Day Range: $3.68 to $4.03
• 52-Week Range: $2.00 to $3.84
• Volume: 86,287 shs
• Average Volume: 239,362 shs
• Market Capitalization: $443.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AQXP Stock Analysis - Frequently Asked Questions

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) announced its quarterly earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43.

What other stocks do shareholders of Aquinox Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), XOMA Royalty (XOMA), Alnylam Pharmaceuticals (ALNY) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/08/2018
• Today: 8/29/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AQXP
• CIK: 1404644
• Web: www.aqxpharma.com
• Phone: 604-629-9223
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.13%
• Return on Assets: -28.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 63.17
• Quick Ratio: 63.17

Sales & Book Value

• Annual Sales: $25 million
• Price / Sales: 17.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.09 per share
• Price / Book: 6.10

Miscellaneous

• Outstanding Shares: 23,540,000
• Free Float: N/A
• Market Cap: $443.49 million
• Optionable: Not Optionable
• Beta: -7.37